^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • trastuzumab brengitecan (BL-M07D1)
    1d
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2026 --> May 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan)
    1d
    AcceleRET Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).
    Trial termination
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    1d
    Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    1d
    Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P3, N=290, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • fluorouracil topical
    1d
    A Phase II Study of ILKN421H With Pembrolizumab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, iLeukon Therapeutics, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    2d
    Surgical Pembro +/- Olaparib w TMZ for rGBM (clinicaltrials.gov)
    P2, N=78, Recruiting, L. Nicolas Gonzalez Castro, MD, PhD | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    2d
    NeoSenti: A Phase 2 Clinical Trial Evaluating the Efficacy of a Single Administration of Pembrolizumab in the Neoadjuvant Setting. (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Universitair Ziekenhuis Brussel
    New P2 trial
    |
    Keytruda (pembrolizumab)
    2d
    KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=161, Active, not recruiting, ModernaTX, Inc. | N=242 --> 161 | Trial completion date: Aug 2027 --> Nov 2027 | Trial primary completion date: Aug 2027 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)
    2d
    NCI-2019-08626: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
    2d
    Safe Stop Trial Melanoma (2024-516937-10-01`2018-001384-23)
    P2/3, N=200, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    2d
    Safe Stop ipi-nivo (2024-516938-34-00`2022-002673-28)
    P2/3, N=80, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)